Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 21, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for April 18, 2008 Subscribe to this News Feed      
 

Pfizer Opens New Development Centre

BRUSSELS, Belgium (Business Wire EON/PRWEB ) April 18, 2008 -- A new development centre for veterinary vaccines which will accelerate the development of new animal health products has been opened by Pfizer as part of its annual $300 million (US dollar) commitment to research and development.

This is an historic occasion for Pfizer Animal Health
The new centre is located on the Louvain-la-Neuve scientific plant near Brussels.

News Image "This is an historic occasion for Pfizer Animal Health, said Juan Ramon Alaix, president of Pfizer Animal Health, "because it is our first pilot plant in Europe for developing animal vaccines. It also demonstrates the strength and value of our continuing partnership with our PGM colleagues.

The new facility houses the development operations for products and processes in the area of formulation, filling and lyophilisation of products. The companys decision to establish its development centre on the same site at which new products will be manufactured is a strategic one. The decision makes it possible for the production site to become more involved in developing new products.

The plant is at the cutting edge of biotechnologies and aseptic operations and employs over 200 people. New on the site is an integrated line for filling vaccines in plastic vials which is dedicated to manufacturing vaccines for pigs which includes the product, Improvac. This is a vaccine to combat boar taint in pigs and is a viable alternative to physical castration. The vaccine has a huge potential as it combines the search for economic advantages with the welfare of animals.

More than 400 finished products from the site are distributed throughout Europe, the US and Brazil and represents an annual volume of 125 million doses with a turnover of approximately $150 million dollars.

MULTIMEDIA GALLERY

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5662069

See the original story at: http://eon.businesswire.com/releases/2008/04/prweb873584.htm

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/RW1wdC1NYWduLVNxdWEtSGFsZi1GYWx1LVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION

Pfizer Animal Health
Mike Keeler, +44 (0)20 8399 1184

ATTACHED FILES

BWAttachment873584-3.jpg

BWAttachment873584-3.jpg

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright